报价延迟最少15分钟:2026/04/21 20:26 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2063 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.43/--
|
|
企业价值
9.65M
|
| 资产负债 |
|
每股账面净值
-0.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage. |
